Smoking cessation product long-term outcome and use data necessary, cmte. members say.
This article was originally published in The Tan Sheet
Executive Summary
SMOKING CESSATION LONG-TERM STUDY HAS "INHERENT VALUE," Carol Falkowski, Minnesota Department of Human Services' Chemical Dependency Division, said at a June 9 meeting of FDA's Drug Abuse Advisory Committee in Bethesda, Md. The committee met to discuss smoking cessation product labeling inclusion of "secondary outcome measures" such as quit success despite relapse, reduction in cigarettes smoked, or diminished withdrawal symptoms. Studies of other drugs that treat addictions examine six-month and one-year outcomes "in spite of limitations" on the data available, she said. "Even if the treatment group is only two weeks or six weeks or eight weeks," there is "inherent value in knowing what the outcome is six months down the road and a year down the road," Falkowski commented.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning